Loading company…
QuantaMatrix develops diagnostic tests for infectious, neurological and cardiovascular diseases.
Founded in 2010 in Seoul, QuantaMatrix develops in vitro diagnostic products, including rapid drug susceptibility tests for tuberculosis, sepsis tests and assays for Alzheimer's disease and cardiovascular conditions. In December 2020, it raised KRW 43.53 billion in an IPO on KOSDAQ, selling 1.7 million shares at KRW 25,500 each.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in